TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsJayaprakash K. Nair, Martin A. Maier, Vasant R. Jadhav, Mark Keating, Kevin Fitzgerald, Stuart Milstein, Kirk Brown, Muthiah Manoharan
Life of this patent
Estimating the term…
Abstract
The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated ocular diseases.
Claims33
1-3. (canceled)
A double stranded RNAi agent for inhibiting expression of TTR in a cell, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double stranded region;
- wherein the sense strand comprises the nucleotide sequence 5′-UGGGAUUUCAUGUAACCAAGA—3′ of (SEQ ID NO:12) and the antisense strand comprises the nucleotide sequence 5′—UCUUGGUUACAUGAAAUCCCAUC -3′ of(SEQ ID NO:
- 13);
- wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand comprise a modification;
- and
- wherein one or more lipophilic moieties are conjugated to one or more internal positions on at least one strand, or one or more positions on at least one strand within the double stranded region.
(canceled)
8-14. (canceled)
16-22. (canceled)
(canceled)
27-34. (canceled)
36-57. (canceled)
59-78. (canceled)
A double stranded ribonucleic acid (RNAi) agent that inhibits expression of transthyretin (TTR) in a cell, comprising a sense strand and an antisense strand forming a double stranded region,
- wherein each of the sense strand and the antisense strand independently comprise nucleotide sequences differing by no more than 4 modified nucleotides from the sense and antisense strand nucleotide sequences of a duplex selected from the group consisting of
- 5'- usgsgga(Uhd)UfuCfAfUfguaaccaasgsa - 3' of SEQ ID NO:
- 15 and
- 5'- VPusCfsuugGfuuAfcaugAfaAfucccasusc - 3' of SEQ ID NO:
- 17;
- 5'- usgsgga(Uhd)UfuCfAfUfguaaccaasgsa - 3' of SEQ ID NO:
- 15 and
- 5'- VPuCfuugGfuuAfcaugAfaAfucccasusc - 3' of SEQ ID NO:
- 62;
- 5' - usgsgga(Uhd)UfuCfAfUfguaaccaasgsa - 3' of SEQ ID NO:
- 15 and
- 5' - VPusCfsuugGf(Tgn)uAfcaugAfaAfucccasusc - 3' of SEQ ID NO:
- 102;
- and
- 5'- usgsgga(Uhd)UfuCfAfUfguaaccaasgsa - 3' of SEQ ID NO:
- 15 and
- 5'- usCfsuugGfuuAfcaugAfaAfucccasusc - 3' of SEQ ID NO:
- 16,
- wherein a, c, g, and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Cf, Gf, and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- (Uhd) is 2′-O-hexadecyl-uridine-3′-phosphate;
- (Tgn) is thymidine-glycol nucleic acid (GNA)S-Isomer;
- s is a phosphorothioate linkage;
- and VP is a vinyl phosphonate.
81-83. (canceled)
(canceled)
A double stranded RNAi agent for inhibiting expression of transthyretin (TTR) in a cell, wherein the RNAi agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises the nucleotide sequence 5′-usgsgga(Uhd)UfuCfAfUfguaaccaasgsa- 3′ of SEQ ID NO:
- 15 and the antisense strand comprises the nucleotide sequence 5′-VPusCfsuugGfuuAfcaugAfaAfucccasusc- 3′ of (SEQ ID NO:
- 17),
- wherein a, c, g, and u are 2′-O-methyladenosine-3′-phosphate, 2′-O-methylcytidine-3′-phosphate, 2′-O-methylguanosine-3′-phosphate, and 2′-O-methyluridine-3′-phosphate, respectively;
- Af, Cf, Gf, and Uf are 2′-fluoroadenosine-3′-phosphate, 2′-fluorocytidine-3′-phosphate, 2′-fluoroguanosine-3′-phosphate, and 2′-fluorouridine-3′-phosphate, respectively;
- s is a phosphorothioate linkage;
- (Uhd) is 2′-O-hexadecyl-uridine-3′-phosphate;
- and VP is a vinyl phosphonate.
(canceled)
(canceled)
96-104. (canceled)
Dependencies are inferred from the claim text.